Compare Charles River Laboratories Intl. Inc (CRL) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Essex Property Trust, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Essex Property Trust, Inc. trades at $269.13 (market cap $17.26B). The key difference: Essex Property Trust, Inc. is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Essex Property Trust, Inc. for 111 Days on average.
| CRL | ESS | |
|---|---|---|
Market Cap | $14.23B | $17.26B |
Volume | 1,176,885 | 454,464 |
Sector | Health | Real Estate |
52-Week High | $310.77 | $298.33 |
52-Week Low | $149.93 | $239.61 |
Typical Hold Time | 33 Days | 111 Days |
Enterprise Value | $17.06B | $23.86B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
ESS trades at $268.05, down 1.63% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with Q3 2026 results pending. Revenue reached $1.89B in 2025, with a net income margin of 21.48%, while valuation ratios like a P/E of 41.83 suggest a premium. Recent news highlights strong Q2 2026 results, raised guidance, and a declared dividend of $2.59 per share.
The outlook is cautiously optimistic, supported by operational strength and resolved litigation, but high valuation and earnings volatility pose risks. Analyst consensus is a Buy with a $303.41 price target, indicating potential upside, though investors should monitor debt levels and consistent earnings delivery against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
